Gert Hoeffken

2.1k total citations
29 papers, 1.5k citations indexed

About

Gert Hoeffken is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Gert Hoeffken has authored 29 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 6 papers in Cardiology and Cardiovascular Medicine and 6 papers in Oncology. Recurrent topics in Gert Hoeffken's work include Pulmonary Hypertension Research and Treatments (18 papers), Lung Cancer Treatments and Mutations (5 papers) and Pneumonia and Respiratory Infections (4 papers). Gert Hoeffken is often cited by papers focused on Pulmonary Hypertension Research and Treatments (18 papers), Lung Cancer Treatments and Mutations (5 papers) and Pneumonia and Respiratory Infections (4 papers). Gert Hoeffken collaborates with scholars based in Germany, Belgium and United States. Gert Hoeffken's co-authors include Michael Halank, Roland Wensel, Hans-Juergen Seyfarth, Marius M. Hoeper, Ralf Ewert, Tobias Welte, Hans‐Dieter Orzechowski, Heinz‐Peter Schultheiss, Richard Strauß and Élise Schaefer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and CHEST Journal.

In The Last Decade

Gert Hoeffken

27 papers receiving 1.4k citations

Peers

Countries citing papers authored by Gert Hoeffken

Since Specialization

Citations

This map shows the geographic impact of Gert Hoeffken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gert Hoeffken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gert Hoeffken more than expected).

Fields of papers citing papers by Gert Hoeffken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gert Hoeffken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gert Hoeffken. The network helps show where Gert Hoeffken may publish in the future.

Co-authorship network of co-authors of Gert Hoeffken

This figure shows the co-authorship network connecting the top 25 collaborators of Gert Hoeffken. A scholar is included among the top collaborators of Gert Hoeffken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gert Hoeffken. Gert Hoeffken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer 2017 ·SHILAP Revista de lepidopterología ·Wolfgang Schuette, Claus-Peter Schneider, Walburga Engel-Riedel, Christian Schumann, Martin Kohlhäeufl, Monika Serke, Gert Hoeffken, C. Kortsik, Martin Reck	8
2	5017Subcutaneous treprostinil for the treatment of non-operable chronic thromboembolic pulmonary hypertension: a randomized, controlled trial (CTREPH) 2017 ·European Heart Journal ·Roela Sadushi‐Kolici, Pavel Jansa, Grzegorz Kopeć, Adam Torbicki, (unknown), Gert Hoeffken, Nika Skoro‐Sajer, Iveta Šimková, Kristóf Karlócai, Regina Steringer‐Mascherbauer, Miroslav Samaržija, Barbara Salobir, Walter Klepetko, Jaroslav Lindner, Iréne Lang	1
3	Haemoptysis due to pulmonary venous stenosis 2014 ·European Respiratory Review ·S. Braun, Ivan Platzek, Klaus Zöphel, Matthias Weise, Martin Kolditz, Michael Halank, Gert Hoeffken	23
4	Ambrisentan Improves Exercise Capacity and Symptoms in Patients with Portopulmonary Hypertension 2011 ·European Respiratory Journal ·Michael Halank, Lars Knudsen, Hans-Juergen Seyfarth, Ralf Ewert, (unknown), Martin Kolditz, Gert Hoeffken, Marius M. Hoeper	0
5	Combined vasomodulatory therapy for severe pulmonary hypertension in chronic hypersensitivity pneumonitis. 2010 ·PubMed ·Dirk Koschel, Martin Kolditz, Gert Hoeffken, Michael Halank	2
6	New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality 2009 ·Thorax ·Santiago Ewig, Norbert Birkner, Richard Strauß, Élise Schaefer, J Pauletzki, Helge Bischoff, Paul Schraeder, Tobias Welte, Gert Hoeffken	297
7	Plasma big-endothelin in pre- versus postcapillary pulmonary hypertension 2009 ·Pneumologie ·(unknown), Alexander Schmeißer, Gert Hoeffken, Michael Halank	1
8	Experience with inhaled iloprost and bosentan in portopulmonary hypertension 2007 ·European Respiratory Journal ·Marius M. Hoeper, Hans-Juergen Seyfarth, Gert Hoeffken, Hubert Wirtz, Edda Spiekerkoetter, Mathias W. Pletz, Tobias Welte, Michael Halank	115
9	Portopulmonary hypertension 2006 ·Journal of Gastroenterology ·Michael Halank, Ralf Ewert, Hans-Juergen Seyfarth, Gert Hoeffken	2
10	Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension 2006 ·European Respiratory Journal ·Marius M. Hoeper, Hanno Leuchte, Michael Halank, Heinrike Wilkens, F. Joachim Meyer, Hans-Juergen Seyfarth, Roland Wensel, (unknown), H. J. Bremer, Stefan Kluge, Gert Hoeffken, Jürgen Behr	216
11	Portopulmonary hypertension 2006 ·Journal of Gastroenterology ·Michael Halank, Ralf Ewert, Hans-Juergen Seyfarth, Gert Hoeffken	21
12	Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension 2006 ·Wiener klinische Wochenschrift ·Michael Halank, Martin Kolditz, Christian Opitz, Gert Hoeffken, Ralf Ewert	7
13	Portopulmonale Hypertonie 2005 ·Zeitschrift für Gastroenterologie ·Michael Halank, (unknown), Martin Kolditz, Gert Hoeffken	3
14	Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan 2005 ·Wiener Medizinische Wochenschrift ·Michael Halank, Martin Kolditz, Stephan Miehlke, (unknown), Alexander Schmeißer, Gert Hoeffken	17
15	Bosentan therapy for portopulmonary hypertension 2005 ·European Respiratory Journal ·Marius M. Hoeper, Michael Halank, Christian Marx, Gert Hoeffken, Hans-Juergen Seyfarth, J. Schauer, J Niedermeyer, J Winkler	137
16	Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens 2004 ·European Journal of Clinical Microbiology & Infectious Diseases ·Gert Hoeffken, David A. Talan, (unknown), (unknown), Shurjeel H Choudhri, Daniel Haverstock, (unknown), D. Church	15
17	Outcome and prognostic features of intensive care unit treatment in patients with hematological malignancies 2002 ·Intensive Care Medicine ·Frank Kroschinsky, Matthias Weise, Thomas Illmer, Mathias Haenel, Martin Bornhaeuser, Gert Hoeffken, Gerhard Ehninger, Ulrich S. Schuler	91
18	The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia 2001 ·Respiratory Medicine ·Gert Hoeffken, H.P. Meyer, J H Winter, Lise M Verhoef	66
19	Big Endothelin-1 and Endothelin-1 Plasma Levels Are Correlated With the Severity of Primary Pulmonary Hypertension 2001 ·CHEST Journal ·(unknown), Ralf Ewert, Michael Halank, Roland Wensel, Hans‐Dieter Orzechowski, Heinz‐Peter Schultheiss, Gert Hoeffken	291
20	Multiple myeloma in a patient at risk for AIDS. 1990 ·PubMed ·(unknown), Roland Baur, (unknown), Gert Hoeffken, (unknown)	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact